Robert Kelley's most recent trade in Talis Biomedical Corp was a trade of 500,000 Stock option (right to buy) done . Disclosure was reported to the exchange on April 7, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Talis Biomedical Corp | Robert Kelley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2023 | 500,000 | 500,000 | - | - | Stock option (right to buy) | |
| Talis Biomedical Corp | Robert Kelley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 723,560 | 723,560 | - | - | Stock Option (right to buy) | |
| Talis Biomedical Corp | Robert Kelley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2021 | 450,000 | 450,000 | - | - | Stock Option (right to buy) | |
| Talis Biomedical Corp | Robert Kelley | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2021 | 130,000 | 427,202 | - | - | Stock Option (right to buy) |